A. CHANAN-KHAN Et Al. , "Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study," LANCET ONCOLOGY , vol.17, no.2, pp.200-211, 2016
CHANAN-KHAN, A. Et Al. 2016. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. LANCET ONCOLOGY , vol.17, no.2 , 200-211.
CHANAN-KHAN, A., CRAMER, P., Demirkan, F., Fraser, G., SILVA, R. S., GROSICKI, S., ... PRISTUPA, A.(2016). Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. LANCET ONCOLOGY , vol.17, no.2, 200-211.
CHANAN-KHAN, Asher Et Al. "Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study," LANCET ONCOLOGY , vol.17, no.2, 200-211, 2016
CHANAN-KHAN, Asher Et Al. "Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study." LANCET ONCOLOGY , vol.17, no.2, pp.200-211, 2016
CHANAN-KHAN, A. Et Al. (2016) . "Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study." LANCET ONCOLOGY , vol.17, no.2, pp.200-211.
@article{article, author={Asher CHANAN-KHAN Et Al. }, title={Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study}, journal={LANCET ONCOLOGY}, year=2016, pages={200-211} }